Drug Profile
Tarcocimab tedromer - Kodiak Sciences
Alternative Names: KSI-301Latest Information Update: 12 Apr 2024
Price :
$50
*
At a glance
- Originator Oligasis
- Developer Kodiak Sciences
- Class Antibodies; Biopolymers; Drug conjugates; Eye disorder therapies; Immunoconjugates
- Mechanism of Action Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Diabetic macular oedema; Diabetic retinopathy; Retinal vein occlusion; Wet age-related macular degeneration
Most Recent Events
- 27 Mar 2024 Phase-III clinical trials in Diabetic retinopathy in USA (Intravitreous) (NCT06270836)
- 07 Nov 2023 Tarcocimab tedromer development is ongoing in multiple countries
- 07 Nov 2023 Kodiak Sciences plans a pivotal trial Retinal vein occlusion, Wet age-related macular degeneration, Diabetic macular oedema worldwide